EGFR and metastatic neoplasm: Their implementation into current practice should partially resolve some of the controversies related to this heterogenic pathology, in matters of prognosis in different TNM stages, stage II patient risk stratification, diagnosis of hereditary CRC and likelihood of benefit from 5-FU chemotherapy or anti EGFR therapy in metastatic disease.